CEO
This is a great place to tell people more about yourself and peak their interest.
For more info, they can follow you on social in a click.
CEO
This is a great place to tell people more about yourself and peak their interest.
For more info, they can follow you on social in a click.
CEO
This is a great place to tell people more about yourself and peak their interest.
For more info, they can follow you on social in a click.
Grant Agreement (NFP) for Phase 1 of the CUSTOMED Project
Project Title: Research and Development of Personalized Medical Implants and the Concept of a Future Manufacturing Hospital with the Implementation of Additive Technologies, Bioprinting, and Bioreactor Systems
Project Code: 401103G756
Call Code: PSK-MZ-012-2025-DV-EFRR
Total Eligible Expenditure: €11,223,806.00
Co-financing Rate (EU and State Budget): 89.02%
Non-repayable Financial Contribution (NFP): €9,991,432.10
Beneficiary’s Own Co-financing: €1,232,373.90
MED4CURE IPCEI
On May 28, 2024, in accordance with EU State aid rules, the European Commission (EC) approved the first Important Project of Common European Interest (IPCEI) in the healthcare sector, titled “IPCEI Med4Cure.” The project aims to support key European research, innovation, and first industrial deployment of medical products, as well as innovative pharmaceutical manufacturing processes contributing to the objectives of the European Health Union. It will deliver innovations targeting diseases for which no satisfactory methods of prevention or treatment currently exist, enhance the EU’s preparedness for emerging health threats, and support the development of the European bioeconomy.
The IPCEI Med4Cure project was jointly prepared and notified by six Member States: Belgium, France, Hungary, Italy, Slovakia, and Spain. These countries will provide up to €1 billion in public funding, expected to leverage an additional €5.9 billion in private investments. Within this framework, 13 companies operating in one or more Member States will implement 14 highly innovative projects, resulting in more than 70 planned collaborations.
The Slovak Republic will also be represented in the project by Biomedical Engineering, which successfully met the stringent evaluation criteria of the European Commission. The project contributes to improving healthcare quality and enhancing the EU’s preparedness for emerging health threats. Its objectives include:
• improving drug discovery, particularly in the field of rare diseases,
• developing innovative and more sustainable pharmaceutical manufacturing processes,
• ensuring sustainability of manufacturing technologies for breakthrough therapies, ranging from personalized medicine to the use of advanced digital technologies.
Biomedical Engineering has been awarded the European CUSTOMED project under the IPCEI Med4Cure call. The project brings together dozens of leading European biotechnology companies, including Sanofi (France), OncoRNA (Belgium), Sanofi (Italy), Fagoterapia (Italy), and others.
The CUSTOMED project represents the future of implantology and tissue engineering. The project’s output will be a next-generation technology utilizing 3D bioprinting and bioreactors, combined with artificial intelligence, for the creation of personalized cartilage tissue replacements. Using this technology, patients may, for example, receive new biological intervertebral discs derived from their own tissues. The facility will also serve for testing various types of newly developed pharmaceuticals for serious diseases. As part of a “manufacturing hospital” concept, CUSTOMED technology offers hope to patients suffering from diseases and damage to bone and cartilage tissue and enables faster access to innovative therapies.
